Bambusa Therapeutics Inc. shares slipped 7% in its trading debut after the early-stage biotech focused on dermatology and autoimmune diseases raised $168.9 million in a US initial public offering.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.